Biotech News
Related news
KNSAKiniksa2026-10-27 11:30 EST
Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
KYMRKymera2026-10-22 20:01 EST
Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
ARGXArgenx2026-10-15 05:00 EST
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
REGNRegeneron Pharmaceuticals2026-09-24 20:05 EST
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
BNTXBioNTech2026-10-20 10:45 EST
BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026
BMYBMYBristol-Myers Squibb Company2026-09-18 10:59 EST
Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
SNGXSOLIGENIX2026-11-06 12:30 EST
Soligenix Announces Recent Updates and Third Quarter 2026 Financial Results
AVTXAvalo Therapeutics2026-11-05 12:00 EST
Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates
SABSSAB Biotherapeutics2026-10-29 12:30 EST
SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET
BMYBMYBristol-Myers Squibb Company2026-10-29 10:59 EST
Bristol Myers Squibb Reports Third Quarter Financial Results for 2026
Kiniksa
IL-1 Cardiovascular Franchise Kiniksa Pharmaceuticals develops and commercializes therapies for diseases with strong biological rationale, with an emphasis on cardiovascular inflammation. Its portfolio is centered on blocking interleukin-1 alpha and beta signaling. ARCALYST ARCALYST, or rilonacept, is a weekly subcutaneous IL-1 cytokine...
Recent company news
KNSAKiniksa2026-10-27 11:30 EST
Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
KNSAKiniksa2026-10-22 20:01 EST
Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026
KNSAKiniksa2026-09-04 20:01 EST
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
KNSAKiniksa2026-08-07 20:01 EST
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
KNSAKiniksa2026-07-28 11:30 EST
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
Stock data
- Close
- 88.34 USD
- Market cap
- 3.61B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States